Docetaxel (taxanes) and Alopecia: is the FAERS signal real?
Docetaxel (taxanes) ↔ Alopecia
Reporting over time (stimulated-reporting check)
Reporting spiked in 2017, 2018, 2019, 2020, 2021 — 68% of all 16,935 reports arrived in two years (2018–2019). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Docetaxel is a taxane chemotherapy, and hair loss is a near-universal, mechanistically direct consequence of its action on rapidly dividing cells — including the hair-follicle matrix. In a randomized trial, alopecia was recorded in roughly a third of patients on docetaxel versus under 2% on pembrolizumab, a striking and entirely expected difference. Alopecia is not merely cosmetic; it is among the most distressing chemotherapy side effects, and its severity is dose- and schedule-dependent.
Regulatory basis: docetaxel prescribing information (alopecia among the most common adverse reactions); confirmed by a randomized comparator arm (trial data below). A class effect of the taxanes and most cytotoxic chemotherapies.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Hair loss begins weeks after the first cycle, after exposure |
| Strength | met | PRR 30, and ~36% incidence in a randomized comparator arm |
| Consistency | met | Reproduced in every taxane trial and cohort |
| Specificity | partial | A class effect of cytotoxic chemotherapy, not molecule-unique |
| Biological gradient | partial | Severity varies with dose, schedule, and agent |
| Plausibility | met | Direct cytotoxicity to rapidly dividing follicle cells — named mechanism |
| Coherence | met | Coheres with the drug's antimitotic action |
| Experiment | met | Hair regrows after treatment stops — a clean dechallenge/rechallenge |
| Analogy | met | Shared with other taxanes and anthracyclines |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — docetaxel vs pembrolizumab in NSCLC (NCT01905657, KEYNOTE-010)
| Term (as recorded) | Docetaxel (n=309) | Pembrolizumab 2 mg/kg (n=339) | Pembrolizumab 10 mg/kg (n=343) |
|---|---|---|---|
| Alopecia (other events) | 110 | 6 | 5 |
About 36% of docetaxel patients had alopecia recorded versus ~1.5–1.8% on pembrolizumab — a large, randomized, textbook-consistent contrast that directly confirms the expected effect. View on ClinicalTrials.gov →